Clinical Trials Directory

Trials / Completed

CompletedNCT04040647

Tolerance of Early Postoperative Mobilization and Ambulation

Tolerance of Early Mobilization and Ambulation the Day of Colorectal and Bariatric Surgery in an Enhanced Recovery Program

Status
Completed
Phase
Study type
Observational
Enrollment
88 (actual)
Sponsor
University of Liege · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Enhanced recovery programme (ERP) includes early postoperative mobilization and ambulation the day of surgery. Data suggest that orthostatic symptoms prevent a large number of patients from ambulating the day of surgery. The investigators plan to include 50 patients scheduled for colorectal surgery and bariatric surgery in an ERP. A 6-min walk test (6MWT) will be performed before surgery, 3 hour after the end of surgery, and 24 hour after surgery. The day of surgery a 2-min walk test will be realized.

Detailed description

Enhanced recovery programme (ERP) includes early postoperative mobilization and ambulation the day of surgery. Data suggest that orthostatic symptoms prevent a large number of patients (up to 50%) from ambulating the day of surgery. The investigators plan to include 50 patients scheduled for colorectal surgery and bariatric surgery in an ERP. The primary endpoint will be the ability to get out of the bed and sit in an armchair. Orthostatic symptom will be recorded. The secondary endpoint will be a 6-min walk test (6-MWT). This test will be performed before surgery, 3 hour after the end of surgery, and 24 hour after surgery. The day of surgery a 2-min walk test (2-MWT) will be realized. Correlation of the ability to early ambulate and postoperative course (adherence to ERP, complications) will be analyzed.

Conditions

Interventions

TypeNameDescription
BEHAVIORALmobilization and ambulation6-min walk test (6-MWT)

Timeline

Start date
2019-09-15
Primary completion
2020-04-01
Completion
2020-04-01
First posted
2019-08-01
Last updated
2020-05-14

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT04040647. Inclusion in this directory is not an endorsement.